Prothena Corporation plc PRTA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -11.31%
- 1 year
- -19.18%
- Open
- 8.79
- Prev close
- 8.88
- Mkt cap
- 434.82M
- Vol
- 452.30K
- Avg vol
- 472.70K
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.35
- High
- 8.90
- Forward P/E
- -3.57
- Beta
- 0.16
- Short ratio
- 17.35
- Inst. own
- 96.97%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 15.72
- 200-d avg
- 20.26
- 1y target
- 49.75
News
5 days ago defenseworld.net
Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares of Company Stock
Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully acquired 50,000 shares of the company's stock in a transaction on Friday, October 23rd. The shares were…
5 days ago defenseworld.net
Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Stock
Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 100,000 shares of the business's stock in a transaction that occurred on Thursday, October 22nd.…
1 week ago defenseworld.net
Prothena (NASDAQ:PRTA) Shares Break Below Two Hundred Day Moving Average – What’s Next?
Prothena Corporation plc (NASDAQ: PRTA - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.26 and traded…
1 week ago zacks.com
Prothena's Partnership Strategy: Growth Driver or Limitation?
PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.
2 weeks ago defenseworld.net
Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Price Target of $24.57
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat.com…
3 weeks ago defenseworld.net
Prothena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 125,000 Shares
Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) major shareholder William Scully purchased 125,000 shares of the business's stock in a transaction on Wednesday, October 7th. The stock was…
3 weeks ago zacks.com
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better…
1 month ago zacks.com
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
1 month ago defenseworld.net
Prothena Corporation plc (NASDAQ:PRTA) Receives $24.57 Consensus PT from Analysts
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm,…
1 month ago businesswire.com
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference.
2 months ago zacks.com
KMDA or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for…
2 months ago zacks.com
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
-
2 months ago benzinga.com
CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of…
2 months ago zacks.com
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $1.86 per share a year ago.
2 months ago businesswire.com
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quarter and first six months of 2026 and provided business highlights.
3 months ago defenseworld.net
Prothena (NASDAQ:PRTA) Share Price Passes Below 200-Day Moving Average – Time to Sell?
Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $9.46 and traded as…
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
3 months ago benzinga.com
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results and raising its FY26 EPS guidance. Other gaining stocks include SLGB, HIHO, WNW, CHNR, RDGT, ULBI,…
3 months ago zacks.com
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
4 months ago zacks.com
SRPT or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value…
-
5 months ago benzinga.com
UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share
https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/xslF345X06/primary_doc.xml
5 months ago zacks.com
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
-
5 months ago benzinga.com
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20
Citizens analyst Jason N. Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $19 to $20.
-
5 months ago benzinga.com
Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $(0.34) by 276.47 percent. This is a 153.57 percent increase over losses of…
5 months ago businesswire.com
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
6 months ago benzinga.com
Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter…
6 months ago businesswire.com
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy.
-
8 months ago benzinga.com
RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $12
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $11 to $12.
-
8 months ago benzinga.com
Prothena Corp Q4 EPS $(0.40) Beats $(0.54) Estimate, Sales $21.000K Miss $1.334M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.54) by 25.93 percent. This is a 62.96 percent increase over losses of…
8 months ago benzinga.com
Earnings Scheduled For February 19, 2026
Earnings Scheduled For February 19, 2026
8 months ago benzinga.com
Exploring Prothena Corp's Earnings Expectations
Exploring Prothena Corp's Earnings Expectations
11 months ago benzinga.com
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
-
11 months ago benzinga.com
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19
Citizens analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $11 to $19.
-
11 months ago benzinga.com
Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a…
11 months ago benzinga.com
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.
-
11 months ago benzinga.com
Prothena Presents Phase 2 Clinical Study Data For Coramitug For Treatment Of ATTR Amyloidosis With Cardiomyopathy American Heart Association's Circulation Journal
Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the…
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $30
HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $20 to $30.
-
11 months ago benzinga.com
RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11
RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $10 to $11.
-
11 months ago benzinga.com
Prothena Corp Q3 Adj. EPS $(0.68) Beats $(0.69) Estimate, Sales $2.415M Miss $6.639M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.69) by 1.02 percent. This is a 38.18 percent increase over losses of…
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
1 year ago benzinga.com
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
1 year ago benzinga.com
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
1 year ago benzinga.com
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
1 year ago benzinga.com
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.